

Gastroplastía Endoscópica



Dr. Ricardo Funke


Jefe Departamento de Cirugía

Jefe Centro de Nutrición y Bariátrica


Clínica Las Condes

IFSO Worldwide Survey 2016: Primary, Endoluminal, and Revisional Procedures

Luigi Angrisani¹  • A. Santonicola² • P. Iovino² • A. Vitiello¹ • K. Higa^{3,4} • J. Himpens⁵ • H. Buchwald⁶ • N. Scopinaro⁷



Penetración estimada: Cirugía vs Fármacos



Tenis

El anuncio más polémico de la Super Bowl: Serena Williams se inyecta GLP-1 ante millones para adelgazar

Controvertido anuncio de Serena Williams pinchándose durante la Super Bowl para promocionar un fármaco para adelgazar



ro

Weight Loss Sexual Health Fertility Hair Skin Daily Health Top Products What We Treat

Serena's healthier on Ro

↓ 34 lbs

in a year on GLP-1s

Start your journey

Serena Williams' journey

After kids, she was doing everything right but nothing worked. Ro finally helped her get back to her strongest self.

Average weight loss in 1 year is 20%, in non-diabetics with obesity, or with overweight plus a weight-related medical condition, with diet and exercise (vs 3.1% with diet and exercise alone). After losing weight with another GLP-1 provider, Serena chose Ro to continue her weight loss journey. She has used both branded vials and pens. Pen injection is shown for visual reference.

Serena Williams mostró su impactante cambio físico tras tomar Ozempic: “Decían que éramos como hombres”

Serena Williams mostró su impactante cambio físico tras tomar Ozempic: **“Decían que éramos como hombres”**




Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity

The SURMOUNT-4 Randomized Clinical Trial

Louis J. Aronne, MD; Naveed Sattar, MD; Deborah B. Horn, DO, MPH; Harold E. Bays, MD; Sean Wharton, MD; Wen-Yuan Lin, MD, PhD; Nadia N. Ahmad, MD, MPH; Shuyu Zhang, MSc; Ran Liao, PhD; Mathijs C. Bunck, MD, PhD; Irina Jouravskaya, MD, PhD; Madhumita A. Murphy, MD; for the SURMOUNT-4 Investigators

Figure 2. Effect of Tirzepatide vs Placebo on Body Weight and Waist Circumference

A Percent change in body weight (week 0-88)



“ESG”



“Endoscopic Sleeve Gastroplasty”

Gastroplastía Endoscópica





OverStitch™ Endoscopic
Suturing System

ESG



©Mayo Clinic



RESEARCH



The International Federation for Surgery and Other Therapies for Obesity (IFSO) Consensus on Clinical Practice in Endoscopic Sleeve Gastroplasty

Consenso IFSO de práctica clínica en ESG

^N
23 expertos

Ricardo V Cohen¹ · Jaime Ponce² · Barham Abu Dayyeh³ · Christine Stier⁴ · Randy Levinson⁵ · Paulina Salminen⁶ · Gerhard Prager⁷

Received: 24 December 2025 / Revised: 19 January 2026 / Accepted: 29 January 2026 / Published online: 5 March 2026


© The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2026



International Surgical Week
The World's Congress of Surgery

51st World Congress of the International Society of Surgery ISS/SIC
Jointly organized with the 34th International Congress of the Mexican Association of Endoscopic Surgery

Resultados del consenso Delphi IFSO 2026 sobre ESG



- **Descenso ponderal:**
 - 13–20% de TWL al año.
 - 15% a los 2 años.
- **Selección de pacientes:**
 - IMC 30–40 kg/m²
 - IMC 27–29,9 kg/m² con enfermedades relacionadas a la obesidad.
- **Favorece sutura de espesor completo a lo largo de la curvatura mayor.**
- **Evitar una sutura excesiva del fundus.**
- **Reflujo: no hay evidencia que produzca.**
- Los eventos adversos serios reportados se mantienen bajos (<2%).



RESEARCH



Endoscopic Sleeve Gastropasty for the Treatment of Metabolic Syndrome: A Systematic Review and Meta-analysis

Mark Hanscom¹ · Muhammad Usman Baig¹ · Drew Wright¹ · Laith Baqain¹ · Kate Elise Johnson¹ · Vivek Kumbhari² · Shelby Sullivan³ · Barham Abu Dayyeh⁴ · SriHari Mahadev¹ · Carolyn Newberry¹ · Kartik Sampath¹ · David Carr-Locke¹ · Christopher Thompson⁵ · Reem Sharaiha¹

Received: 21 December 2024 / Revised: 25 February 2025 / Accepted: 28 March 2025 / Published online: 8 April 2025

© The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2025

Meta-análisis de ESG en síndrome metabólico

N

10 estudios / 4,320 pacientes

Revisión sistemática y meta-análisis.

Búsqueda en múltiples bases hasta marzo de 2024.

Incluyó 1 RCT y estudios observacionales.



International Surgical Week
The World's Congress of Surgery

51st World Congress of the International Society of Surgery ISS/SIC
Jointly organized with the 34th International Congress of the Mexican Association of Endoscopic Surgery




Fig. 4 Fasting blood glucose (FBG) 1-year post-ESG




Fig. 5 Homeostatic model assessment for insulin resistance (HOMA-IR) 1-year post-ESG

- A 12 meses: mejoría de DM2 en 72%, dislipidemia en 65% e HTA en 60%.
- HbA1c: -0.40%; glucemia en ayunas: -6.50 mg/dL.
- HOMA-IR: -2.20.
- También disminuyeron LDL


Endoscopic sleeve gastropasty for treatment of class 1 and 2 obesity (MERIT): a prospective, multicentre, randomised trial



Barham K Abu Dayyeh, Fateh Bazerbachi, Eric J Vargas, Reem Z Sharaiha, Christopher C Thompson, Bradley C Thaemert, Andre F Teixeira, Christopher G Chapman, Vivek Kumbhari, Michael B Ujiki, Jeanette Ahrens, Courtney Day, the MERIT Study Group, Manoel Galvao Neto, Natan Zundel, Erik B Wilson



Key Results at 52 Weeks:

- Mean %EWL: 49.2% in ESG group vs 3.2% in control group ($p<0.0001$)
- Mean %Total Body Weight Loss: 13.6% ESG vs 0.8% control ($p<0.0001$)
- $\geq 25\%$ EWL: 77% of ESG patients vs 12% controls ($p<0.0001$)



Endoscopic sleeve gastroplasty for treatment of class 1 and 2 obesity (MERIT): a prospective, multicentre, randomised trial

Barham K Abu Dayyeh, Fateh Bazerbachi, Eric J Vargas, Reem Z Sharaiha, Christopher C Thompson, Bradley C Thaemert, Andre F Teixeira, Christopher G Chapman, Vivek Kumbhari, Michael B Ujiki, Jeanette Ahrens, Courtney Day, the MERIT Study Group, Manoel Galvao Neto, Natan Zundel, Erik B Wilson



- 68% mantuvo ≥25% EWL
- 83% mantuvo su peso desde la semana 52 al control de 2 años

RESEARCH

Efficacy of Revisional Endoscopic Sleeve Gastropasty After Laparoscopic Sleeve Gastrectomy

John Deng¹ · Julia Wool¹ · Ronald Blanco Montecino² · Alvaro Cadillo Arbaiza¹ · Luyu Xie¹ · Sarah E. Messiah¹ · Sunil Matthew¹ · Shannon Shiffer¹ · Jaime P. Almandoz¹ · Anna Tavakkoli¹

Received: 14 November 2024 / Revised: 14 November 2024 / Accepted: 28 December 2024 / Published online: 8 January 2025
© The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2025

N = 55 pacientes



International Surgical Week
The World's Congress of Surgery

51st World Congress of the International Society of Surgery ISS/SIC
Jointly organized with the 34th International Congress of the Mexican Association of Endoscopic Surgery


Fig. 1 Total body weight loss (%) at 12 months

Cohorte retrospectiva, posterior a GVM.

Seguimiento hasta 24 meses.

La **pérdida de peso total porcentual (TBWL)** fue de:

- 8,6% al año (n=37),
- 10,7% a los 18 meses (n=31),
- 12,6% a los 24 meses (n=18).





Endoscopic Sleeve Gastropasty: 6-Year Outcomes in 1,377 Patients

Manoel Galvao Neto¹ · Mohit Bhandari¹ · Manoj Reddy¹ · Mahak Bhandari¹ · Sonika Ranganath¹ · Susmit Kosta¹ · Winni Mathur¹

Received: 26 October 2025 / Revised: 7 January 2026 / Accepted: 21 January 2026 / Published online: 17 February 2026
© The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2026

Abstract

Background Endoscopic sleeve gastropasty (ESG) is a minimally invasive endoluminal bariatric procedure, but long-term outcomes beyond 5 years remain limited. This study reports 6-year weight loss, comorbidity outcomes, and safety data from a large single-center cohort.

- Cohorte retrospectiva observacional de un centro. Inclusión 2019-2025.
- N=1377.




International Surgical Week
The World's Congress of Surgery

51st World Congress of the International Society of Surgery ISS/SIC
Jointly organized with the 34th International Congress of the Mexican Association of Endoscopic Surgery

Fig. 3 Weight Loss Outcomes (%TWL) Over Time



Fig. 4 Excess Weight loss (EWL%) Over Time



- %TWL medio: 21.2% al año y 14.4% a 6 años.
- %EWL medio: 56.9% al año y 43.4% a 6 años.



International Surgical Week
The World's Congress of Surgery

51st World Congress of the International Society of Surgery ISS/SIC
Jointly organized with the 34th International Congress of the Mexican Association of Endoscopic Surgery

Table 3 Comorbidity outcomes at 6 years

Comorbidity	Prevalence Before Sur- gery (%)	Resolution/ Improvement at 6 Years (%)	p-value
Type 2 diabetes mellitus	33.3	51.2	<0.001
Hypertension	44.3	65.8	<0.001
Obstructive sleep apnea	37.0	89.9	<0.001
Dyslipidemia	34.9	73.6	<0.001

- Mejoría/resolución a 6 años:
- DM2 51.2%
- HTA 65.8%
- OSA 89.9%
- **D**islipidemia 73.6%.



International Surgical Week
The World's Congress of Surgery

51st World Congress of the International Society of Surgery ISS/SIC
Jointly organized with the 34th International Congress of the Mexican Association of Endoscopic Surgery

RESEARCH

Comparing Endoscopic Sleeve Gastropasty (ESG) and Laparoscopic Sleeve Gastrectomy (LSG) 30-Day Outcomes and Healthcare Utilization: A Multi-Centered Retrospective Cohort Study of 506,597 Patients

Valentin Mocanu¹ · Emily Jordan² · Jerry Dang¹ · Thomas Shin²

Received: 15 January 2025 / Revised: 25 March 2025 / Accepted: 23 April 2025 / Published online: 28 April 2025

© The Author(s) 2025

ESG vs LSG: resultados a 30 días

^N
506,597 pacientes

Cohorte retrospectiva multicéntrica.

MBSAQIP 2020-2023.

2285 ESG vs 504,312 LSG.



International Surgical Week
The World's Congress of Surgery

51st World Congress of the International Society of Surgery ISS/SIC
Jointly organized with the 34th International Congress of the Mexican Association of Endoscopic Surgery

Conclusión:

- No hubo diferencia significativa en complicaciones serias a 30 días.
 - La visita a emergencias fue menor con ESG: 4.6% vs 7.2%.
 - La estadía hospitalaria fue menor con ESG: 0.19 vs 1.21 días.
-
- **ESG no aumentó complicaciones serias y redujo uso de guardia.**



REVIEW ARTICLE

Endoscopic sleeve gastropasty (ESG): indications and results—a systematic review

Christine Karolina Stier¹  · Patrick Téoule² · Barham K. Abu Dayyeh^{3,4}

Received: 30 October 2024 / Accepted: 7 January 2025 / Published online: 28 January 2025

© The Author(s) 2025

Revisión sistemática
de indicaciones y
resultados


N

**44 estudios /
15,714 ESG**



International Surgical Week
The World's Congress of Surgery

51st World Congress of the International Society of Surgery ISS/SIC
Jointly organized with the 34th International Congress of the Mexican Association of Endoscopic Surgery



- TBWL media:
15.66% a 6 meses y
17.56% a 12 meses.

- TBWL media a largo
plazo: 15.2% a 24
meses y 15.9% a 60
meses.

Fig. 3 Mean percentage of excess weight loss (%EWL) and total body weight loss (%TBWL) at specific time points following endoscopic sleeve gastroplasty (ESG). For context, the number of individuals and articles at each time point are included above the bars



Conclusión

ESG es una terapia **segura, eficaz y duradera** para sobrepeso asociado a síndrome metabólico y obesidad tipo 1–2, que conduce a una pérdida de peso significativa y a la mejora metabólica.

Puede servir como un **punto o una alternativa** a la cirugía bariátrica, especialmente para pacientes que no son candidatos o que no desean someterse a cirugía.

Es una técnica efectiva como **revisión** de manga gástrica previa.



International Surgical Week
The World's Congress of Surgery

51st World Congress of the International Society of Surgery ISS/SIC
Jointly organized with the 34th International Congress of the Mexican Association of Endoscopic Surgery


Boston
Scientific

Advancing science for life™



Gastroplastia Endoscópica

Instalación del Equipo



Gastroplastia Endoscopica

Ubicación de
Primer punto

Primer y segundo
Punto

Gastroplastia Endoscopica

Primera linea de
Sutura

Gastroplastia Endoscopica

Segunda linea

Primera sutura

Gastroplastia Endoscopica

Corte

Gastroplastia Endoscopica

Revision después

La primera sutura

Gastroplastia Endoscopica

Segunda Sutura

Pre Cinch

Gastroplastia Endoscopica

Corte

Gastroplastia Endoscopica

Tercera Sutura

Gastroplastia Endoscopica

Endoscopia

Posterior


Endoscopia
Posterior

Nuestra experiencia en 3 años

615 EG


Seguimiento

150 Pacientes



Nuestra experiencia en 3 años

Edad	36,57
IMC	30,91



	6 MESES	12 MESES
TWL	14,4 %	12,8 %
EWL	85,6 %	85,1%

Nuestra experiencia en 3 años

Complicaciones

150 Pacientes



4 Pacientes
(2,6%)

2 HDA

1 NEUMOPERITONEO

1 PANCREATITIS

Sin requerimiento de intervención quirúrgico ni exploración endoscópica, el 100 % respondió a tratamiento médico

